Modality
Vaccine
MOA
CDK4/6i
Target
C5
Pathway
Neuroinflam
Pancreatic CaNASHADPKD
Development Pipeline
Preclinical
May 2018
→ Jan 2030
PreclinicalCurrent
NCT08271356
842 pts·ADPKD
2018-05→2030-01·Active
842 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-223.8y awayInterim· ADPKD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Active
Catalysts
Interim
2030-01-22 · 3.8y away
ADPKD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08271356 | Preclinical | ADPKD | Active | 842 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |